Erythropoietin and cancer, a double-edged sword.
This editorial is focused on the double controversial action of erythropoietin, acting as anticancer agent and as a promoting cancer agent.
Ribatti
Domenico
D
D000740:Anemia / Q000188:drug therapy*; D018450:Disease Progression; D004921:Erythropoietin / Q000096:biosynthesis / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000503:physiopathology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017467:Receptors, Erythropoietin / Q000235:genetics; D015996:Survival Rate
D012333:RNA, Messenger; D017467:Receptors, Erythropoietin; D004921:Erythropoietin